2016 Fiscal Year Final Research Report
Development of novel molecular targeted therapy for rejection after organ transplantation using HSP90 inhibitor
| Project/Area Number |
15K20099
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
TANAKA Toshiaki
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Keywords | Heat shock protein 90 / HSP90阻害剤 / 臓器・組織移植 / 拒絶反応 |
|---|
| Outline of Final Research Achievements |
We have previously published that HSP90 is a potential serological biomarker of acute rejection (AR) after renal transplantation and plays a role in the development of AR in organ transplantation. The aim of this study was to investigate the immunosuppressive effect of the HSP90 inhibitor 17DMAG in organ transplantation. Administration of HSP90 inhibitor 17DMAG prolonged graft survival versus vehicle group in murine skin and heart transplantations. The allograft of the 17DMAG group decreased neutrophil infiltration into the allografts. In 17DMAG-treated mice, Th1 cell cytokine were significantly reduced. In MLRs analysis, 17DMAG significantly inhibited the proliferation of CD4 T lymphocytes and CD19 B cells. The results of our research suggest that HSP90 inhibition by 17DMAG may have therapeutic potential against AR in allotransplantation.
|
| Free Research Field |
移植免疫学
|
